Publicaciones (24) Publicaciones de MARÍA CONCEPCIÓN GARCÍA GARCÍA

2022

  1. Editorial: Cannabinoids as potential treatment for neurological diseases

    Frontiers in Neuroscience

2021

  1. Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  2. Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease

    Molecules, Vol. 26, Núm. 11

  3. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice

    Molecular and Cellular Neuroscience, Vol. 110

  4. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

2020

  1. Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

    Neurobiology of Disease, Vol. 141

2019

  1. Development of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease

    Molecules, Vol. 24, Núm. 15

2018

  1. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies

    Methods in Enzymology (Academic Press Inc.), pp. 175-198

2016

  1. Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia

    British Journal of Pharmacology, pp. 2069-2079

  2. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 64, pp. 200-208

  3. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice

    Pharmacological Research, Vol. 110, pp. 181-192

2015

  1. Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson's disease

    Neuroscience Letters, Vol. 587, pp. 1-4

2013

  1. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?

    British Journal of Clinical Pharmacology, Vol. 75, Núm. 2, pp. 323-333

  2. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors

    Neuropharmacology, Vol. 75, pp. 155-163

2011

  1. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ 9-THCV in animal models of Parkinson's disease

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1495-1506

2010

  1. Different Susceptibility to the Parkinson's Toxin MPTP in Mice Lacking the Redox Master Regulator Nrf2 or Its Target Gene Heme Oxygenase-1

    PLoS ONE, Vol. 5, Núm. 7, pp. e11838

  2. The endocannabinoid system as a target for the treatment of neuronal damage

    Expert Opinion on Therapeutic Targets, Vol. 14, Núm. 4, pp. 387-404

2009

  1. Cannabinoid CB1 receptors are early DownRegulated followed by a further UpRegulation in the basal Ganglia of mice with deletion of specific park genes

    Journal of Neural Transmission, Supplementa, pp. 269-275

  2. Cannabinoids and Parkinson's Disease

    CNS and Neurological Disorders - Drug Targets, Vol. 8, Núm. 6, pp. 432-439